FGF2 and acute liver failure: Teng and colleagues introduced a strategy employing rat hepatocytes and human fetal liver stromal cells (hFLSCs) for acute liver failure treatment, showing that the co-encapsulated approach significantly improves survival and hepatic function, partly due to the release of basic fibroblast growth factor (bFGF) (80).